Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Pharma Tech
FDA calls for stronger potency upkeep in CGT manufacturing
The FDA’s CBER director said patients should have assurance that administered products will work as intended.
Read Full Article
Pharma Tech
AbbVie inks $757m migraine-focused deal with Brise PharmaceuticalsÂ
AbbVie and Brise have shared details on this migraine deal two years after the pair originally forged it.
Read Full Article
Pharma Tech
Lonza to acquire five US manufacturing sites from Merck KGaA
Lonza has entered an agreement for the acquisition of five US CDMO sites from Merck KGaA, bringing 1,100 employees into Lonza's workforce.
Read Full Article
Pharma Tech
Bavarian Nordic secures four-year UK vaccine supply deal
Bavarian Nordic has secured a four-year contract from the UK Government to supply its MVA-BN vaccine, used for the prevention of mpox and smallpox.
Read Full Article
Express Pharma
US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavirÂ
Under the existing agreement, injectable lenacapavir will be available at US$40 per person per year across 120 countries covered by Gilead’s voluntary licence. The post US FDA grants tentative approval for Dr. Reddy’s twice-yearly injectable lenacapavir appeared first on Express Pharma.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Nov 4, 2026, 1:01 AM
Wockhardt seeks 14-year data shield for India-made drugs
Delays in regulatory approval system leave domestic innovators with three to four years less effective patent life than in the US and Europe, Khorakiwala told ET adding that, time lost at different stages of the process can substantially shrink the commercial (sales) window.
Pharma Tech
Nov 3, 2026, 4:23 PM
FDA calls for stronger potency upkeep in CGT manufacturing
The FDA’s CBER director said patients should have assurance that administered products will work as intended.
Pharma Tech
Nov 3, 2026, 2:21 PM
AbbVie inks $757m migraine-focused deal with Brise PharmaceuticalsÂ
AbbVie and Brise have shared details on this migraine deal two years after the pair originally forged it.
PharmaShots
Nov 3, 2026, 11:36 AM
Merck KGaA to Divest its CDMO Business to Lonza
Shots: Merck KGaA has signed a definitive agreement to divest the CDMO business of its Life Science sector to Lonza for a mid-triple-digit million-euro amount, with closing expected in mid-2027, subject to regulatory approvals & other conditions The deal covers development & manufacturing services for complex modalities across sites in Carlsbad (CA), Madison & Verona… The post Merck KGaA to Divest its CDMO Business to Lonza appeared first on PharmaShots.
PharmaShots
Nov 3, 2026, 11:36 AM
Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US
Shots: Teva & Samsung Bioepis have entered a license & commercialization agreement for 2 FDA-approved immunology biosimilars in the US: infliximab-abda (biosimilar to Remicade) & ETICOVO (etanercept-ykro; biosimilar to Enbrel) Teva will gain US commercialization rights to etanercept-ykro at closing & to infliximab-abda in Q3’27, while Samsung Bioepis remains responsible for regulatory oversight & manufacturing;… The post Teva and Samsung Bioepis Enter into an Agreement to Commercialize Two FDA-Approved Biosimilars in the US appeared first on PharmaShots.
PharmaShots
Nov 3, 2026, 11:34 AM
Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon
Shots: Rhythm Pharmaceuticals has amended its global exclusive license agreement with LG Chem for bivamelagon (formerly LB54640), an investigational oral small-molecule MC4R agonist Rhythm will pay 50M in 4 fixed installments through Sep 2029 (0M upfront), while the prior low-to-mid-single-digit royalty is replaced by a 1% royalty on global sales of its MC4R portfolio from… The post Rhythm Pharmaceuticals and LG Chem Amend Exclusive License Agreement for Bivamelagon appeared first on PharmaShots.
News
Latest industry coverage
Google News
Nov 4, 2026, 3:20 AM
Vietnam unlikely to meet 80% drug production target by 2030 - Healthcare Asia Magazine
Vietnam unlikely to meet 80% drug production target by 2030Â Â Healthcare Asia Magazine
Google News
Nov 4, 2026, 3:05 AM
Pricey pills: Editorial on limits of free-market pricing in pharmaceutical industry - Telegraph India
Pricey pills: Editorial on limits of free-market pricing in pharmaceutical industry  Telegraph India
Google News
Nov 4, 2026, 3:05 AM
India Enhances Drug Manufacturing Accountability with New Amendments - Observer Voice
India Enhances Drug Manufacturing Accountability with New Amendments  Observer Voice
Google News
Nov 4, 2026, 2:57 AM
Pfizer promotes insider to CFO - CFO Dive
Pfizer promotes insider to CFOÂ Â CFO Dive
Google News
Nov 4, 2026, 2:01 AM
Incheon Free Economic Zone Authority Expands Foundation for Future Industries in K-Content and Biotech, Pursues Zone at Southern Tip of Ganghwado Island - ě•„ě‹śě•„ę˛˝ě ś
Incheon Free Economic Zone Authority Expands Foundation for Future Industries in K-Content and Biotech, Pursues Zone at Southern Tip of Ganghwado IslandÂ Â ě•„ě‹śě•„ę˛˝ě ś
Google News
Nov 4, 2026, 12:35 AM
Compliance backlogs delay drug batch releases at pharma plants: Study - Business Standard
Compliance backlogs delay drug batch releases at pharma plants: Study  Business Standard
Google News
Nov 4, 2026, 12:03 AM
Anthropic IPO: Meet Vas Narasimhan, Indian origin director on its board - The Financial Express
Anthropic IPO: Meet Vas Narasimhan, Indian origin director on its board  The Financial Express
Google News
Nov 3, 2026, 11:54 PM
Bukwang Pharma exports diabetes drug tech to Saudi, pursues local production - Chosunbiz
Bukwang Pharma exports diabetes drug tech to Saudi, pursues local production  Chosunbiz
Google News
Nov 3, 2026, 11:30 PM
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment - PR Newswire
Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment  PR Newswire
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer